We consider the IDH1(R132H) as a "therapeutic mutation" due to its ability to improve progression free and overall survival in glioblastoma patients [213]. We described how the IDH1(R132H) muta- tion can act synergistically with ketogenic metabolic therapy (KMT) to simultaneous target both the...